[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
Dr. Jeffrey Medin, PhD, is a Co-Founder of Glafabra and the principal inventor of the Live-cel platform.
With co-founder Dr. Ronan Foley, he led the Canadian FACTS trial (NCT02800070), which followed five Fabry patients for five years and produced the published data Glafabra is built on (PMID 36816757). On October 2 he presented at IFFD 2026 at Jikei University in Tokyo.
For diligence purposes: the inventor of the platform remains directly involved in the company developing it.
See the Sep 9 post for what the FACTS data does and does not show.
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Chris Hopkins @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0